產(chǎn)品中心Cell Resources
聯(lián)系我們CONTACT US
- 400-999-210024小時服務(wù)熱線
BPH-1 (人前列腺增生細(xì)胞) (STR鑒定正確)
貨號:CL-0865
規(guī)格:1×10?cells/T25培養(yǎng)瓶
價格: ¥1800
生長培養(yǎng)基:RPMI-1640+20%FBS+20 ng/mL testosterone + 0.5% ITS-G(100×)+1% P/S
產(chǎn)品概述
名稱 | BPH-1 (人前列腺增生細(xì)胞) (STR鑒定正確) |
別稱 | BPH1; Benign Prostatic Hyperplasia-1 |
種屬 | 人 |
生長特性 | 貼壁細(xì)胞 |
細(xì)胞形態(tài) | 上皮細(xì)胞樣 |
凍存條件 | 凍存液:55% 基礎(chǔ)培養(yǎng)基+40%FBS+5%DMSO 溫度:液氮 |
培養(yǎng)方案A(默認(rèn)) |
生長培養(yǎng)基:
培養(yǎng)條件:
氣相:空氣,95%;CO2,5%, 溫度:37℃
|
推薦傳代比例 | 1:3-1:5 |
推薦換液頻率 | 2-3次/周 |
背景描述 | prostate epithelial cells from a 68-year-old man with benign prostate hyperplasia; cells were immortalized with SV-40 large T-antigen; cells were described in the literature to express cytokeratins 8, 18, and 19 (but not 14) and to metabolize prostatic androgens. |
年齡(性別) | 男性;68歲 |
組織來源 | 前列腺 |
細(xì)胞類型 | 轉(zhuǎn)化細(xì)胞系 |
生物安全等級 | BSL-1 |
倍增時間 | ~50 hours (DSMZ=ACC-143) |
保藏機(jī)構(gòu) | DSMZ; ACC-143 |
STR鑒定
-
STR位點信息
Amelogenin X, Y CSF1PO 10,12 D2S1338 17 D3S1358 16 D5S818 11,12 D7S820 10,11 D8S1179 10,15 D13S317 11,12 D16S539 9 D18S51 10,16 D19S433 12.1,15 D21S11 28,32.2 FGA 21,24 PentaD 14 PentaE 7,10 TH01 6,7 TPOX 8,12 vWA 17 D6S1043 11,12 D12S391 22 D2S441 14 -
STR鑒定圖
參考文獻(xiàn)
-
Identification and functional activity of Nik related kinase (NRK) in benign hyperplastic prostate(2024/03/09)
作者:Weixiang He, Zelin Tian, Bingchen Dong
期刊:Journal of Translational Medicine
DOI:10.1186/s12967-024-05048-3
影響因子 :7.400
引用產(chǎn)品:CL-0865
-
Mechanism of RhoA regulating benign prostatic hyperplasia: RhoA-ROCK-β-catenin signaling axis and static & dynamic dual roles(2023/10/20)
作者:Shidong Shan, Min Su, Yan Li
期刊:MOLECULAR MEDICINE
DOI:10.1186/s10020-023-00734-2
影響因子 :5.700
引用產(chǎn)品:CL-0865
-
STEAP4 modulates cell proliferation and oxidative stress in benign prostatic hyperplasia(2023/10/20)
作者:Jiang Liu, Wei Zhou, Liang Yang
期刊:CELLULAR SIGNALLING
DOI:10.1016/j.cellsig.2023.110933
影響因子 :4.800
引用產(chǎn)品:CL-0865
-
Epigenetic-related Gene-based Prognostic Model Construction and Validation in Prostate Adenocarcinoma(2024/05/08)
作者:Youyou Li, Chao Li, Longxiang Wu
期刊:Heliyon
DOI:10.1016/j.heliyon.2024.e30941
影響因子 :4.000
引用產(chǎn)品:CL-0865
FAQs
Q:{{item.question}}
A:
產(chǎn)品資料
識別碼示意圖